IT'S A NEW CHEMICAL entity, and no one is sure exactly how it works, but ticlopidine hydrochloride appears to work better than aspirin in staving off stroke in high-risk patients, according to the results of a 55-center trial.
That was the word from William K. Hass, MD, one of the principal investigators of the Ticlopidine/Aspirin Stroke Study. Hass summarized the study's results at the recent 14th International Joint Conference on Stroke and Cerebral Circulation in San Antonio, Tex.
Hass, professor of neurology at New York (NY) University School of Medicine, told the conference that the drug, developed by Syntex Corporation, Palo Alto, Calif, was superior to aspirin in preventing both fatal and nonfatal strokes. He said that the side effects were minor and reversible.
The study undertaken in 1981 involved 3069 patients who had suffered a transient ischemic attack or a more prolonged, but reversible, ischemic deficit within the 90